Abstract
For decades, cystoscopy and urine cytology have been the mainstay for monitoring superficial urothelial carcinoma patients for tumor recurrence. However, urine cytology has poor sensitivity for urothelial carcinoma and, consequently, numerous investigators have been endeavoring to develop more sensitive assays for the detection of urothelial carcinoma. This article presents an overview of the types of new assays that have been developed for urothelial carcinoma detection but focuses primarily on the features and performance of a new fluorescence in situ hybridization assay for urothelial carcinoma detection known as Vysis® UroVysion.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 507-519 |
| Number of pages | 13 |
| Journal | Expert Review of Molecular Diagnostics |
| Volume | 3 |
| Issue number | 4 |
| DOIs | |
| State | Published - Jul 2003 |
Keywords
- Bladder cancer
- Bladder tumor markers
- FISH
- Urine cytology
- Urothelial carcinoma
- Vysis® UroVysion
ASJC Scopus subject areas
- Pathology and Forensic Medicine
- Molecular Medicine
- Molecular Biology
- Genetics